Sexual wellness startup Allo Health will use the capital to expand its clinic network, strengthen technological capabilities, ...
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream ...
Bengaluru-based Allo Health raises INR 16 Cr in Pre-Series A round led by Zerodha's Rainmatter to expand clinic network and ...
Allo Health raises Rs. 16 crore to expand India’s largest sexual health ecosystem: Our Bureau, Bengaluru Wednesday, March 12, 2025, 17:45 Hrs [IST] Allo Health, India’s leadin ...
Sexual health and wellness startup Allo Health has raised Rs 16 crore in a pre-series A round led by Zerodha's Rainmatter, with participation from existing investors. The funds will be used to ...
March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for ...
FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy ...
Key upcoming catalysts include interim data for Cema-cel’s ALPHA3 by mid-2025, and initial trials for ALLO-329 in autoimmune diseases starting in H1, 2025. To date, all commercially available ...
The following is a summary of “Prognostic impact of effusion in multiple body cavities after allogeneic hematopoietic stem cell transplantation,” published in the March 2025 issue of International ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback